Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: IR response on IBIS

IR response on IBIS

posted on Aug 19, 2009 02:46PM

Hi Angela,

Since PTSC retained the services of Ibis Consulting, can you please explain what value they have brought to the company? Have they been successful in attracting institutional investors? If so, to what end?

Thank you, XXXX

IBIS was engaged to raise the PTSC profile to appropriate institutional investors. During the first part of their engagement, they booked several speaking/presentation slots at investor conferences that were focused on smaller cap technology companies, and were responsible for setting one-on-ones with investors whose investing profile might include PTSC as the PDSG strategy was implemented. Given the economic meltdown, it was evident that the timing was not good to spend significant resources on building institutional interest. IBIS is still maintaining information flow to the groups that indicated some interest, but we have reduced the level of activity for the time being.

As the economy recovers and we have additional announced successes from PDSG, we will resume a higher level of activity in pursuit of those investors.

Best regards,

Investor Relations

Share
New Message
Please login to post a reply